摘要目的 研究新型非肽类肾素抑制剂阿利吉仑对高血压患者缓激肽(BK)和高敏C反应蛋白(hs-CRP)的影响.方法 选取门诊进行治疗的轻、中度原发性高血压患者80例.按随机数字表法分为雷米普利组、阿利吉仑75 mg/d组、阿利吉仑150 mg/d组、阿利吉仑300 mg/d组,每组20例,分别接受雷米普利5 mg/d,阿利吉仑75、150及300 mg/d治疗.采用酶联免疫吸附试验法检测hs-CRP水平,采用放射免疫法检测BK水平.结果 阿利吉仑75 mg/d组、阿利吉仑150 mg/d组、阿利吉仑300 mg/d组治疗后BK及hs-CRP水平分别为(5.06±1.61)、(5.05±1.87)、(5.27±1.39)μg/L和(0.38±0.11)、(0.25±0.05)、(0.33±0.11)mg/L,均显著低于雷米普利组[(7.12±1.12)μg/L、(0.49±0.19) mg/L] (P值均＜0.05)；阿利吉仑各剂量组治疗后收缩压、舒张压与雷米普利组治疗后比较差异无统计学意义(P值均＞ 0.05).结论 阿利吉仑具有很好的降压效果,且不会引起BK及hs-CRP的增高.

abstractsObjective To explore the value of a novel non-peptide renin inhibitor aliskiren on hypertension patients,and analyze the change of bradykinin (BK) and high sensitive C-reactive protein (hs-CRP).Methods Eighty patients with mild to moderate hypertension were selected.Patients were randomized divided into ramipril group,aliskiren 75 mg/d group,aliskiren 150 mg/d group,aliskiren 300 mg/d group with 20 cases each by random digits table method and received the following types of intervention:ramipril 5 mg/d,aliskiren 75 mg/d,aliskiren 150 mg/d and aliskiren 300 mg/d.Enzyme-linked immunosorbent assay method was used for detecting hs-CRP.Radioimmunoassay method was used for detecting BK.Results After treatment,the levels of BK and hs-CRP in aliskiren 75 mg/d group,aliskiren 150 mg/d group and aliskiren 300 mg/d group [(5.06 ± 1.61),(5.05 ± 1.87),(5.27 ± 1.39) μg/L and (0.38 ± 0.11 ),(0.25 ± 0.05),(0.33 ± 0.11 ) mg/L] were significantly lower than those in ramipril group [ (7.12 ± 1.12) μ g/L,(0.49 ± 0.19) mg/L ] (P＜0.05 ).After treatment,the levels of SBP and DBP had no significant difference among the four groups (P＞0.05).Conclusion Aliskiren has a very good effect in decreasing blood pressure and does not cause the levels of BK and hs-CRP increasing.